

Hiroko Yamashita

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9231594/publications.pdf>

Version: 2024-02-01

135
papers

5,151
citations

71102

41
h-index

98798

67
g-index

140
all docs

140
docs citations

140
times ranked

7414
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an <i>ad hoc</i> analysis of the JBCRG-C06 Safari study. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 545-553.	1.3	4
2	Brief collaborative care intervention to reduce perceived unmet needs in highly distressed breast cancer patients: randomized controlled trial. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 244-251.	1.3	2
3	How pregnancy and childbirth affect the working conditions and careers of women surgeons in Japan: findings of a nationwide survey conducted by the Japan Surgical Society. <i>Surgery Today</i> , 2021, 51, 309-321.	1.5	10
4	The disease sites of female genital cancers of BRCA1/2-associated hereditary breast and ovarian cancer: a retrospective study. <i>World Journal of Surgical Oncology</i> , 2021, 19, 36.	1.9	4
5	Safety Evaluation of Initial CT-P6 Administration for 30 min during the Switch from Reference Trastuzumab in Maintenance Infusion: A Multicenter Observational Study. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 474-477.	1.4	3
6	Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer. <i>Scientific Reports</i> , 2021, 11, 8109.	3.3	4
7	Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis. <i>Supportive Care in Cancer</i> , 2021, 29, 8059-8067.	2.2	6
8	Endothelial ganglioside GM3 regulates angiogenesis in solid tumors. <i>Biochemical and Biophysical Research Communications</i> , 2021, 569, 10-16.	2.1	7
9	The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer. <i>Cancers</i> , 2021, 13, 110.	3.7	11
10	Genetic heterogeneity during breast cancer progression in young patients. <i>Breast</i> , 2021, 60, 206-213.	2.2	3
11	Current conditions and issues of physicians and working conditions at institutions accredited by the Japanese Breast Cancer Society. <i>Breast Cancer</i> , 2020, 27, 159-165.	2.9	0
12	Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study. <i>Breast Cancer</i> , 2020, 27, 389-398.	2.9	6
13	Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1380-1385.	1.3	7
14	<i>HER2</i> Gene Amplification in ER-positive <i>HER2</i> Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence. <i>Anticancer Research</i> , 2020, 40, 645-652.	1.1	26
15	Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi. <i>Internal Medicine</i> , 2020, 59, 2155-2160.	0.7	1
16	Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer. <i>Oncology Letters</i> , 2019, 17, 2177-2186.	1.8	20
17	Elimination of tumor hypoxia by eribulin demonstrated by ¹⁸ F-FMISO hypoxia imaging in human tumor xenograft models. <i>EJNMMI Research</i> , 2019, 9, 51.	2.5	11
18	Flower isoforms promote competitive growth in cancer. <i>Nature</i> , 2019, 572, 260-264.	27.8	96

#	ARTICLE	IF	CITATIONS
19	Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. <i>ESMO Open</i> , 2019, 4, e000476.	4.5	17
20	Predicting metastasis in clinically negative axillary lymph nodes with minimum apparent diffusion coefficient value in luminal A-like breast cancer. <i>Breast Cancer</i> , 2019, 26, 628-636.	2.9	8
21	Effects of serum estradiol and progesterone on estrogen-regulated gene expression in breast cancers of premenopausal patients. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 12-21.	1.3	3
22	Two Cases of Solitary Colonic Metastasis of Breast Cancer Performed Colectomy. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2019, 80, 2157-2163.	0.0	0
23	Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. <i>ESMO Open</i> , 2018, 3, e000314.	4.5	15
24	Hereditary breast cancer: molecular biology and management update. <i>International Journal of Clinical Oncology</i> , 2018, 23, 35-35.	2.2	0
25	Analysis of gender-based differences among surgeons in Japan: results of a survey conducted by the Japan Surgical Society. Part 1: Working style. <i>Surgery Today</i> , 2018, 48, 33-43.	1.5	22
26	Comparison of quality of life between 2-year and 3-or-more-year administration of leuprolerin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2018, 26, 933-945.	2.2	0
27	Factors associated with prolonged time to treatment failure with fulvestrant 500mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study. <i>Current Medical Research and Opinion</i> , 2018, 34, 49-54.	1.9	8
28	Analysis of gender-based differences among surgeons in Japan: results of a survey conducted by the Japan Surgical Society. Part. 2: personal life. <i>Surgery Today</i> , 2018, 48, 308-319.	1.5	20
29	Tamoxifen withdrawal in women with progressive metastatic breast cancer: a case series of six patients. <i>International Cancer Conference Journal</i> , 2018, 7, 142-147.	0.5	3
30	<i>PIK3CA</i> mutation, reduced AKT serine 473 phosphorylation, and increased ER α serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer. <i>Oncotarget</i> , 2018, 9, 17711-17724.	1.8	10
31	Collaborative care intervention for the perceived care needs of women with breast cancer undergoing adjuvant therapy after surgery: a feasibility study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 213-220.	1.3	8
32	Breast cancer detected as an incidental finding on ^{99m} Tc-MIBI scintigraphy. <i>Acta Radiologica Open</i> , 2017, 6, 205846011771566.	0.6	1
33	Automatic Estimation of Volumetric Breast Density Using Artificial Neural Network-Based Calibration of Full-Field Digital Mammography: Feasibility on Japanese Women With and Without Breast Cancer. <i>Journal of Digital Imaging</i> , 2017, 30, 215-227.	2.9	12
34	Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. <i>Breast Cancer</i> , 2017, 24, 473-482.	2.9	19
35	Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women. <i>Oncotarget</i> , 2017, 8, 65759-65769.	1.8	9
36	Two Cases of Recurrent Breast Cancer with Ophthalmic Metastases. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2017, 78, 660-664.	0.0	1

#	ARTICLE	IF	CITATIONS
37	Two Cases of Breast Cancer in Juvenile Patients in Their Thirties with PTEN Hamartoma Tumor Syndrome. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2017, 78, 2624-2628.	0.0	0
38	Correlation between contrast-enhanced ultrasound findings and clinicopathological factors in breast cancer. <i>Choonpa Igaku</i> , 2017, 44, 41-48.	0.0	0
39	Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence. <i>Breast Cancer Research</i> , 2016, 18, 73.	5.0	26
40	Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. <i>BMC Cancer</i> , 2016, 16, 230.	2.6	30
41	Fulvestrant 500Âmg in postmenopausal patients with metastatic breast cancer: the initial clinical experience. <i>Breast Cancer</i> , 2016, 23, 617-623.	2.9	11
42	Differences in morphological features and minimum apparent diffusion coefficient values among breast cancer subtypes using 3-tesla MRI. <i>European Journal of Radiology</i> , 2016, 85, 96-102.	2.6	30
43	<scp>GANP</scp> protein encoded on human chromosome 21/mouse chromosome 10 is associated with resistance to mammary tumor development. <i>Cancer Science</i> , 2016, 107, 469-477.	3.9	18
44	Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. <i>Breast Cancer</i> , 2016, 23, 830-843.	2.9	36
45	Strong cytoplasmic expression of NF-ÎB/p65 correlates with a good prognosis in patients with triple-negative breast cancer. <i>Surgery Today</i> , 2016, 46, 843-851.	1.5	6
46	A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5Âyears as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. <i>Breast Cancer</i> , 2016, 23, 499-509.	2.9	11
47	A Case of Breast Cancer with Polyostotic Fibrous Dysplasia that was Indistinguishable from Multiple Bone Metastases. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2016, 77, 1907-1911.	0.0	0
48	Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. <i>Breast Cancer</i> , 2015, 22, 235-244.	2.9	58
49	Difference of patient's perceived need in breast cancer patients after diagnosis. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 75-80.	1.3	18
50	Anxiety in disease-free breast cancer patients might be alleviated by provision of psychological support, not of information. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 929-933.	1.3	14
51	Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. <i>Breast Cancer</i> , 2015, 22, 185-191.	2.9	77
52	FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. <i>Breast Cancer</i> , 2015, 22, 308-316.	2.9	16
53	Identifying Triple-Negative Breast Cancer Using Background Parenchymal Enhancement Heterogeneity on Dynamic Contrast-Enhanced MRI: A Pilot Radiomics Study. <i>PLoS ONE</i> , 2015, 10, e0143308.	2.5	110
54	Tumor biology in estrogen receptor-positive, human epidermal growth factor receptor type 2-negative breast cancer: Mind the menopausal status. <i>World Journal of Clinical Oncology</i> , 2015, 6, 220.	2.3	5

#	ARTICLE	IF	CITATIONS
55	Differential expression of estrogen receptor $\hat{1}$, $\hat{1}^2$, and $\hat{2}$ in lobular and ductal breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1933-1938.	7.1	144
56	Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer. BMC Cancer, 2014, 14, 990.	2.6	49
57	HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients. Japanese Journal of Clinical Oncology, 2014, 44, 619-623.	1.3	11
58	Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2014, 144, 249-261.	2.5	40
59	p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Science, 2014, 105, 81-88.	3.9	63
60	Repression of cathepsin E expression increases the risk of mammary carcinogenesis and links to poor prognosis in breast cancer. Carcinogenesis, 2014, 35, 714-726.	2.8	22
61	Evaluating the 21-gene assay Recurrence Score [®] as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. International Journal of Clinical Oncology, 2014, 19, 607-613.	2.2	54
62	Association of the single nucleotide polymorphism TNRC9 rs3803662 on mammographic density and estrogen receptor-positive breast cancer risk in Japanese women.. Journal of Clinical Oncology, 2014, 32, 1523-1523.	1.6	0
63	Prognostic significance of pre-treatment neutrophil: lymphocyte ratio in Japanese patients with breast cancer. Anticancer Research, 2014, 34, 3819-24.	1.1	32
64	Using the EORTC-QLQ-C30 in clinical practice for patient management: identifying scores requiring a clinician's attention. Quality of Life Research, 2013, 22, 2685-2691.	3.1	82
65	miR-1290 and its potential targets are associated with characteristics of estrogen receptor $\hat{1}$ -positive breast cancer. Endocrine-Related Cancer, 2013, 20, 91-102.	3.1	58
66	Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer. BMC Cancer, 2013, 13, 239.	2.6	16
67	Relationship of tumor and stromal autophagy and endocrine responsiveness in breast cancer tissues.. Journal of Clinical Oncology, 2013, 31, 571-571.	1.6	0
68	High Expression of MicroRNA-210 is an Independent Factor Indicating a Poor Prognosis in Japanese Triple-negative Breast Cancer Patients. Japanese Journal of Clinical Oncology, 2012, 42, 256-263.	1.3	88
69	Perceived Needs, Psychological Distress and Quality of Life of Elderly Cancer Patients. Japanese Journal of Clinical Oncology, 2012, 42, 704-710.	1.3	21
70	Reproductive history and breast cancer risk. Breast Cancer, 2012, 19, 302-308.	2.9	89
71	Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast, 2012, 21, 40-45.	2.2	14
72	Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer. Cancer Science, 2012, 103, 1708-1713.	3.9	8

#	ARTICLE	IF	CITATIONS
73	Phase II randomized trial of toremifene 120 mg compared with exemestane 25 mg after prior nonsteroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 105-105.	1.6	2
74	Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. <i>Cancer Science</i> , 2011, 102, 858-865.	3.9	44
75	Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women. <i>Cancer Science</i> , 2011, 102, 2065-2072.	3.9	41
76	Distinct expressions of microRNAs that directly target estrogen receptor in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 331-339.	2.5	75
77	High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. <i>International Journal of Clinical Oncology</i> , 2011, 16, 512-518.	2.2	24
78	Patient's perceived need and psychological distress and/or quality of life in ambulatory breast cancer patients in Japan. <i>Psycho-Oncology</i> , 2011, 20, 497-505.	2.3	114
79	Patients' Supportive Care Needs and Psychological Distress in Advanced Breast Cancer Patients in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 530-536.	1.3	83
80	Oncologists' Recognition of Supportive Care Needs and Symptoms of Their Patients in a Breast Cancer Outpatient Consultation. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1251-1258.	1.3	41
81	Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor. <i>Breast Cancer</i> , 2010, 17, 254-260.	2.9	11
82	Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. <i>Breast Cancer</i> , 2010, 17, 298-302.	2.9	28
83	Menin, a product of the MEN1 gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 395-407.	2.5	46
84	Recommendations for Adequate Evaluation of Hormone Receptors™ A report of the task force of the Japanese Breast Cancer Society. <i>Oncology Reports</i> , 2010, 24, 299-304.	2.6	5
85	No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 651-656.	1.3	34
86	Reliability and validity of the Japanese version of the Short-form Supportive Care Needs Survey Questionnaire (SCNS-F34). <i>Psycho-Oncology</i> , 2009, 18, 1003-1010.	2.3	52
87	Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. <i>Cancer Science</i> , 2009, 100, 2028-2033.	3.9	50
88	Current research topics in endocrine therapy for breast cancer. <i>International Journal of Clinical Oncology</i> , 2008, 13, 380-383.	2.2	30
89	Loss of heterozygosity at the ATBF1-A locus located in the 16q22 minimal region in breast cancer. <i>BMC Cancer</i> , 2008, 8, 262.	2.6	20
90	Identification of biomarkers in ductal carcinoma in situ of the breast with microinvasion. <i>BMC Cancer</i> , 2008, 8, 287.	2.6	35

#	ARTICLE	IF	CITATIONS
91	Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. <i>BMC Cancer</i> , 2008, 8, 309.	2.6	63
92	Possible Difference in Frequencies of Genetic Polymorphisms of Estrogen Receptor \hat{A} , Estrogen Metabolism and P53 Genes Between Estrogen Receptor-positive and -negative Breast Cancers. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 734-742.	1.3	18
93	miR-206 Expression Is Down-regulated in Estrogen Receptor \hat{A} -Positive Human Breast Cancer. <i>Cancer Research</i> , 2008, 68, 5004-5008.	0.9	287
94	Low phosphorylation of estrogen receptor \hat{A} (ER \hat{A}) serine 118 and high phosphorylation of ER \hat{A} serine 167 improve survival in ER-positive breast cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 755-763.	3.1	76
95	Lactogens Promote Beta Cell Survival through JAK2/STAT5 Activation and Bcl-XL Upregulation. <i>Journal of Biological Chemistry</i> , 2007, 282, 30707-30717.	3.4	76
96	Expression of Estrogen Receptor \hat{A} Wild-type and its Variant ER \hat{A} cx \hat{A} 22 is Correlated with Better Prognosis in Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 820-828.	1.3	74
97	Prognostic Significance of Insulin-like Growth Factor Binding Protein (IGFBP)-4 and IGFBP-5 Expression in Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2007, 37, 575-582.	1.3	54
98	Gpx2 Is an Overexpressed Gene in Rat Breast Cancers Induced by Three Different Chemical Carcinogens. <i>Cancer Research</i> , 2007, 67, 11353-11358.	0.9	64
99	Comparison of Evaluations for Hormone Receptors in Breast Carcinoma Using Two Manual and Three Automated Immunohistochemical Assays. <i>American Journal of Clinical Pathology</i> , 2007, 127, 356-365.	0.7	34
100	Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. <i>Breast Cancer Research</i> , 2007, 9, R34.	5.0	81
101	p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. <i>Breast Cancer Research</i> , 2006, 8, R48.	5.0	79
102	NCOR1 mRNA is an independent prognostic factor for breast cancer. <i>Cancer Letters</i> , 2006, 237, 123-129.	7.2	28
103	Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. <i>Breast Cancer</i> , 2006, 13, 74-83.	2.9	94
104	Low Expression of the Snail Gene is a Good Prognostic Factor in Node-Negative Invasive Ductal Carcinomas. <i>Japanese Journal of Clinical Oncology</i> , 2006, 36, 357-363.	1.3	14
105	Reduced Expression of the Breast Cancer Metastasis Suppressor 1 mRNA Is Correlated with Poor Progress in Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6410-6414.	7.0	59
106	Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 11-16.	2.5	292
107	Phosphorylation of estrogen receptor \hat{A} serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. <i>Breast Cancer Research</i> , 2005, 7, R753-64.	5.0	94
108	ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer. <i>Clinical Cancer Research</i> , 2005, 11, 193-8.	7.0	31

#	ARTICLE	IF	CITATIONS
109	HDAC6 Expression Is Correlated with Better Survival in Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6962-6968.	7.0	269
110	Dominant-negative Stat5 inhibits growth and induces apoptosis in T47D-derived tumors in nude mice. <i>Cancer Science</i> , 2004, 95, 662-665.	3.9	28
111	Clinical significance of the expression of estrogen receptors $\hat{1}\pm$ and $\hat{1}^2$ for endocrine therapy of breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 34-38.	2.3	54
112	Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. <i>Oncogene</i> , 2003, 22, 1638-1652.	5.9	82
113	Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. <i>Cancer Letters</i> , 2003, 189, 97-102.	7.2	83
114	p33ING1b stimulates the transcriptional activity of the estrogen receptor $\hat{1}\pm$ via its activation function (AF) 2 domain. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 87, 57-63.	2.5	18
115	Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. <i>Breast Cancer Research</i> , 2003, 6, R24-30.	5.0	117
116	Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast. <i>Breast Cancer Research</i> , 2003, 5, R250-6.	5.0	20
117	A CASE OF BILATERAL FIBROMATOSIS OF THE BREAST. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan)</i> Tj ETQq1 1 0.784314 rgBT 0.0	0.0	0
118	The role of stat5 in estrogen receptor-positive breast cancer. <i>Breast Cancer</i> , 2002, 9, 312-318.	2.9	17
119	Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast. <i>Breast Cancer Research and Treatment</i> , 2002, 74, 47-53.	2.5	39
120	Role of serine phosphorylation of Stat5a in prolactin-stimulated $\hat{1}^2$ -casein gene expression. <i>Molecular and Cellular Endocrinology</i> , 2001, 183, 151-163.	3.2	80
121	Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast. <i>Breast Cancer</i> , 2001, 8, 98-104.	2.9	22
122	Telomerase Activity Levels for Evaluating the Surgical Margin in Breast-Conserving Surgery. <i>Surgery Today</i> , 2001, 31, 289-294.	1.5	7
123	Serine Phosphorylation of GH-Activated Signal Transducer and Activator of Transcription 5a (STAT5a) and STAT5b: Impact on STAT5 Transcriptional Activity. <i>Molecular Endocrinology</i> , 2001, 15, 2157-2171.	3.7	62
124	Epithelial Defect in Prostates of Stat5a-Null Mice. <i>Laboratory Investigation</i> , 2000, 80, 993-1006.	3.7	41
125	A Lymphoma Growth Inhibitor Blocks Some but Not All Prolactin-stimulated Signaling Pathways. <i>Journal of Biological Chemistry</i> , 1999, 274, 14699-14705.	3.4	7
126	Differential Control of the Phosphorylation State of Proline-juxtaposed Serine Residues Ser725 of Stat5a and Ser730 of Stat5b in Prolactin-sensitive Cells. <i>Journal of Biological Chemistry</i> , 1998, 273, 30218-30224.	3.4	132

#	ARTICLE	IF	CITATIONS
127	Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Research and Treatment, 1997, 42, 173-181.	2.5	50
128	Low frequency loss of heterozygosity in theBRCA1 region in Japanese sporadic breast cancer. Breast Cancer, 1996, 3, 167-172.	2.9	4
129	Microsatellite instability in sporadic human breast cancers. , 1996, 68, 447-451.		48
130	Clinical significance of cathepsin D assay in breast cancer tissues. Journal of Surgical Oncology, 1995, 60, 221-226.	1.7	4
131	Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer. Breast Cancer Research and Treatment, 1993, 28, 215-221.	2.5	8
132	Analysis of Oncogenes and Tumor Suppressor Genes in Human Breast Cancer. Japanese Journal of Cancer Research, 1993, 84, 871-878.	1.7	39
133	Estrogen Receptor, β and $\text{p}23/\text{NDP}$ Kinase Expression in the Intraductal and Invasive Components of Human Breast Cancers. Japanese Journal of Cancer Research, 1992, 83, 859-865.	1.7	32
134	A LONG-TERM SURVIVING CASE OF ADVANCED BREAST CANCER WITH LYMPHANGITIS TYPE LUNG METASTASIS. The Journal of the Japanese Practical Surgeon Society, 1992, 53, 2659-2663.	0.0	0
135	A CASE OF LATELY RECURRENT BREAST CANCER RECOVERED FROM TRANSVERSAL UPPER THORACIC SPINAL CORD LESION. The Journal of the Japanese Practical Surgeon Society, 1992, 53, 2934-2937.	0.0	0